EUCTR2010-023484-17-IT进行中（未招募）1 期
OCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01) - ND
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Soft tissue sarcoma of adults, primary or locally recurrent, with spindle-cell or pleomorphic histology, belonging to one of the following for the randomization (Group1): ? Myxoid-Round Cell Liposarcomas (cellular componen t>5 %) ? Leiomyosarcoma ? Synovial sarcoma ? Malignant Peripheral Nerve Sheat Tumor ? Undifferentiated pleomorphic sarcoma (ex Malignant fibrous histiocytoma) Or belonging to one of the following for the registration (Group 2): ? Myxofibrosarcoma ? Unclassified Spindle Cell ? Pleomorphic Liposarcoma ? Pleomorphic Rabdomiosarcoma Or belonging to either group but not being evaluable for response (re-excision after previous inadequate resection or primary definitive surgery) (Group3) The histological diagnosis must be made according to the WHO criteria and will have to be centrally reviewed before randomization. 2) High malignancy grade: grade 3 of 3, according to Coindre, or grade 2 at biopsy with a radiological evidence of more than 50% of necrosis in the tumor mass. 3) Deep seated extremities, girdles and/or superficial trunk (thoracic or abdominal wall) lesion. 4) Size of primary tumor (visible or previously inadequately resected) >5 cm at instrumental staging (CT, MRI), or locally recurrent of any size. 5) Age > 18 years. 6) ECOG performance status <1. 7) Adequate bone marrow function: WBC >3.500/mm3 leukocytes >1.500/mm3 platelets >150.000/mm3 hemoglobin >11 g%. 8) Adequate renal (creatinine <1.3 mg%), and hepatic function (bilirubin <1.5 mg% and transaminases <2 x n.v. If ALP > 2.5 x ULN, ALP LF and/or GGT = ULN) 9) Adequate cardiac function (FE >50%) 10) Signed informed consent. 11) Complete compliance of the participating center with the protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Pregnancy or lactation. 2) Distant metastasis. 3) Other malignancies within past 5 years, with the exception of carcinoma in situ of cervix and basocellular skin cancers treated with eradicating intent. 4) Sarcoma histotypes other than those mentioned in the inclusion criteria. 5) Prior CT and/or RT. 6) Serious psychiatric disease that precludes informed consent or limits compliance. 7) Medical disease limiting survival to less than two years, limiting compliance or which in the physician’s opinion might interfere significantly with the toxicity of the treatments. 8) Cardiovascular diseases resulting in a New York Heart Association Functional Status >2. 9) Uncontrolled bacterial, viral or fungal infection. 10) Impossibility of ensuring adequate follow-up. 11) Failure to comply with the requirements of the present protocol leading to exclusion of the participating center.
研究者
相似试验
进行中（未招募）
1 期
Histologically based neoadjuvant approch for adults with soft tissue sarcomas of extremities and trunk wallEUCTR2010-023484-17-PLItalian Sarcoma Group450
Unknown
1 期
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue SarcomaSoft Tissue SarcomaNCT00541840Grupo Espanol de Investigacion en Sarcomas24
已完成
1 期
Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue SarcomaAdvanced Soft Tissue SarcomaNCT01684449Grupo Espanol de Investigacion en Sarcomas28
招募中
不适用
Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal SinusSarcoma,Soft TissueNasal Cavity CancerParanasal Sinus CancerSurgeryNCT05614375Eye & ENT Hospital of Fudan University40
招募中
2 期
Pemetrexed, Cisplatin With Soft Tissue SarcomaSarcoma,Soft TissueNCT04605770Yonsei University164